Literature DB >> 20816926

Antipsychotic drugs dose-dependently suppress the spontaneous hyperactivity of the chakragati mouse.

G S Dawe1, R Nagarajah, R Albert, D E Casey, K W Gross, A K Ratty.   

Abstract

The chakragati (ckr) mouse has been proposed as a model of aspects of schizophrenia. The mice, created serendipitously as a result of a transgenic insertional mutation, exhibit spontaneous circling, hyperactivity, hypertone of the dopamine system, reduced social interactions, enlarged lateral ventricles, deficits in pre-pulse inhibition of acoustic startle and deficits in latent inhibition of conditioned learning. In this study, the dose-dependent effects of antipsychotic drugs (haloperidol, pimozide, risperidone, clozapine, olanzapine, ziprasidone, quetiapine and aripiprazole) on the spontaneous hyperactivity of the mice were investigated. All the antipsychotic drugs tested dose-dependently suppressed spontaneous hyperactivity. Aripriprazole, which is known to be a dopamine D2 receptor partial agonist, exhibited a tri-phasic dose-response, initially suppressing hyperactivity at low doses, having little effect on hyperactivity at intermediate doses, and suppressing activity again at high doses. These data suggest that the spontaneous circling and hyperactivity of the ckr mouse may allow screening of candidate antipsychotic compounds, distinguishing compounds with aripriprazole-like profiles.
Copyright © 2010 IBRO. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20816926     DOI: 10.1016/j.neuroscience.2010.08.061

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  5 in total

1.  Altered exploration and sensorimotor gating of the chakragati mouse model of schizophrenia.

Authors:  Jared W Young; Anil Ratty; Gavin S Dawe; Mark A Geyer
Journal:  Behav Neurosci       Date:  2014-04-07       Impact factor: 1.912

2.  Chronic Administration of Pimozide Fails to Attenuate Motor and Pathological Deficits in Two Mouse Models of Amyotrophic Lateral Sclerosis.

Authors:  Silvia Pozzi; Sai Sampath Thammisetty; Jean-Pierre Julien
Journal:  Neurotherapeutics       Date:  2018-07       Impact factor: 7.620

3.  Brain PET Imaging of α7-nAChR with [18F]ASEM: Reproducibility, Occupancy, Receptor Density, and Changes in Schizophrenia.

Authors:  Dean F Wong; Hiroto Kuwabara; Andrew G Horti; Joshua M Roberts; Ayon Nandi; Nicola Cascella; James Brasic; Elise M Weerts; Kelly Kitzmiller; Jenny A Phan; Lorena Gapasin; Akira Sawa; Heather Valentine; Gary Wand; Chakradhar Mishra; Noble George; Michael McDonald; Wojtek Lesniak; Daniel P Holt; Babak B Azad; Robert F Dannals; William Kem; Robert Freedman; Albert Gjedde
Journal:  Int J Neuropsychopharmacol       Date:  2018-07-01       Impact factor: 5.176

4.  Long-term Effects of Aripiprazole Treatment during Adolescence on Cognitive Function and Dopamine D2 Receptor Expression in Neurodevelopmentally Normal Rats.

Authors:  Hyung Jun Choi; Soo Jung Im; Hae Ri Park; Subin Park; Chul-Eung Kim; Seunghyong Ryu
Journal:  Clin Psychopharmacol Neurosci       Date:  2019-08-31       Impact factor: 2.582

5.  Gene-microRNA interactions associated with antipsychotic mechanisms and the metabolic side effects of olanzapine.

Authors:  Danielle M Santarelli; Bing Liu; Carlotta E Duncan; Natalie J Beveridge; Paul A Tooney; Peter R Schofield; Murray J Cairns
Journal:  Psychopharmacology (Berl)       Date:  2013-01-15       Impact factor: 4.530

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.